Center for Public Health Research, San Francisco Department of Public Health, San Francisco, CA, USA.
Division of Prevention Science, Center for AIDS Prevention Studies, University of California, San Francisco, CA, USA.
J Int AIDS Soc. 2020 Jun;23 Suppl 3(Suppl 3):e25539. doi: 10.1002/jia2.25539.
INTRODUCTION: Although transgender women (trans women) often are conflated with men who have sex with men (MSM) in HIV research and services, there are distinct population differences that are important for implementing effective HIV prevention. Our objective was to examine pre-exposure prophylaxis (PrEP) disparities between the two populations and compare individual, social and structural factors that influence differences between MSM and trans women along the PrEP continuum. METHODS: We analysed data from two population-based studies, one with trans women (Trans*National Study, 2016 - 18) and the other with MSM (National HIV Behavioral Surveillance, 2017). Trans women were recruited via respondent-driven sampling and MSM using time location sampling. Key indicators of the PrEP continuum were evaluated, including awareness, health insurance, provider discussions, recent use and adherence. Associations were also examined for PrEP continuum indicators and structural barriers (e.g. employment, homelessness). RESULTS: Transwomen were more likely than MSM to be Latino/a (30.4% vs. 25.8%; prevalence ratio (PR)=1.08, 95% CI 1.02 to 1.14) or African American (7.1% vs. 4.5%; PR = 1.12, 1.02 to 1.24), live at or below the poverty limit (70.7% vs. 15.8%; PR = 1.47; 1.41 to 1.53), be unemployed (50.1% vs. 26.3%; PR = 1.18, 1.13 to 1.24), be homeless (8.4% vs. 3.5%; PR = 1.15, 1.06 to 1.25) and to have less than a college degree (PR = 1.41, 1.34 to 1.48). Trans women were more likely than MSM to have health insurance (95.7% vs. 89.7%, PR = 1.17, 1.06 to 1.28), but less likely than MSM to have heard of PrEP (79.1% vs. 96.7%; PR = 0.77, 0.73 to 0.81), talked with a provider about PrEP (35.5% vs. 54.9%; PR = 0.87, 0.83 to 0.91) and less likely than MSM to have used PrEP in the past six months (14.6% vs. 39.8%; PR = 0.80, 0.76 to 0.84). Among PrEP users, trans women were less likely to report being adherent to PrEP than MSM (70.4% vs. 87.4%; PR = 0.80, 0.70 to 0.91). CONCLUSIONS: We found PrEP disparities for trans women compared to MSM and the need for differentiated implementation strategies to meet the specific PrEP barriers trans women face. Inclusion of trans women's HIV risks is needed in CDC guidance for PrEP. Interventions to increase trans women's awareness of PrEP including at the provider and community level are also needed. Finally, programming that addresses trans women's barriers to housing and income is also needed to reduce PrEP disparities.
简介:尽管跨性别女性(跨性别女性)在艾滋病毒研究和服务中经常与男男性行为者(MSM)混淆,但存在明显的人群差异,这对于实施有效的艾滋病毒预防措施非常重要。我们的目的是研究这两个群体之间的暴露前预防(PrEP)差异,并比较影响 MSM 和跨性别女性在 PrEP 连续体上差异的个体、社会和结构因素。
方法:我们分析了两项基于人群的研究的数据,一项是跨性别女性(跨性别全国研究,2016-18 年),另一项是 MSM(国家艾滋病毒行为监测,2017 年)。通过回应驱动抽样招募跨性别女性,通过时间地点抽样招募 MSM。评估了 PrEP 连续体的关键指标,包括意识、医疗保险、与提供者的讨论、最近使用和坚持。还检查了 PrEP 连续体指标和结构障碍(例如就业、无家可归)之间的关联。
结果:与 MSM 相比,跨性别女性更有可能是拉丁裔/美洲人(30.4%对 25.8%;患病率比(PR)=1.08,95%置信区间(CI)为 1.02 至 1.14)或非裔美国人(7.1%对 4.5%;PR=1.12,1.02 至 1.24),生活在贫困线或以下(70.7%对 15.8%;PR=1.47;1.41 至 1.53),失业(50.1%对 26.3%;PR=1.18,1.13 至 1.24),无家可归(8.4%对 3.5%;PR=1.15,1.06 至 1.25),以及受教育程度低于大学(PR=1.41,1.34 至 1.48)。与 MSM 相比,跨性别女性更有可能拥有医疗保险(95.7%对 89.7%,PR=1.17,1.06 至 1.28),但不太可能听说过 PrEP(79.1%对 96.7%;PR=0.77,0.73 至 0.81),与提供者讨论过 PrEP(35.5%对 54.9%;PR=0.87,0.83 至 0.91),并且在过去六个月中使用 PrEP 的可能性小于 MSM(14.6%对 39.8%;PR=0.80,0.76 至 0.84)。在 PrEP 用户中,跨性别女性坚持使用 PrEP 的比例低于 MSM(70.4%对 87.4%;PR=0.80,0.70 至 0.91)。
结论:我们发现跨性别女性与 MSM 相比,PrEP 存在差异,需要采取差异化的实施策略来满足跨性别女性面临的具体 PrEP 障碍。疾病预防控制中心关于 PrEP 的指南需要纳入跨性别女性的艾滋病毒风险。还需要在提供者和社区层面开展提高跨性别女性对 PrEP 认识的干预措施。最后,还需要制定解决跨性别女性住房和收入障碍的方案,以减少 PrEP 差异。
MMWR Morb Mortal Wkly Rep. 2019-9-20
J Acquir Immune Defic Syndr. 2025-4-15
Open Forum Infect Dis. 2024-9-11
J Acquir Immune Defic Syndr. 2020-5-1
J Acquir Immune Defic Syndr. 2020-4-15
AIDS Patient Care STDS. 2019-5
Endocrinol Metab Clin North Am. 2019-3-23
J Acquir Immune Defic Syndr. 2019-8-1